MapLight Therapeutics, Inc.

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders. Its lead product candidate is ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist intended for schizophrenia and Alzheimer's disease psychosis. The pipeline also includes ML-004 for social communication deficits and irritability in autism spectrum disorder, ML-021 for motor deficits in Parkinson's disease, ML-055 for neuropsychiatric conditions, and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for hyperactivity, impulsivity, and agitation-related disorders. Additionally, the company has a platform that identifies neural circuits causally linked to disease and targets those circuits for therapeutic modulation.

MapLight Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol MPLT. The trading currency is the US Dollar (USD). Being listed on NasdaqGS provides the company with access to a broad base of institutional and retail investors in the United States and globally.

MapLight Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing novel therapies for serious medical conditions, particularly those affecting the central nervous system. The company's work involves advanced drug discovery and clinical development, aiming to bring new treatment options to patients with unmet medical needs.

MapLight Therapeutics is headquartered in Redwood City, California, United States. The company was incorporated in 2018 and was originally known as Alvarado Therapeutics, Inc. It rebranded to MapLight Therapeutics, Inc. in August 2019. The company's location in the San Francisco Bay Area places it within a major biotechnology hub, providing access to talent, research institutions, and potential partners.

MapLight Therapeutics is a clinical-stage biopharmaceutical company that does not yet have approved products or generate revenue from product sales. Its business model focuses on advancing a pipeline of drug candidates through preclinical and clinical development, with the goal of obtaining regulatory approval and eventually commercializing therapies for CNS disorders. Key pipeline products include ML-007C-MA for schizophrenia and Alzheimer's disease psychosis, ML-004 for autism spectrum disorder, ML-021 for Parkinson's disease motor deficits, ML-055 for neuropsychiatric conditions, and ML-009 for hyperactivity and agitation disorders. The company also leverages a proprietary platform that identifies disease-linked neural circuits for targeted therapeutic modulation.